A variant of TP53 gene (rs 1625895, 13494g>A) is associated with neoplasm localization in patients with uterine leiomyoma
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-2.16195Keywords:
neoplasm localization, risk of development, TP53 gene variants, uterine leiomyoma.Abstract
Summary. Background: Uterine leiomyoma (UL) is the most common benign neoplasm of the uterus. It is still unknown surely what exactly initiates transformation of the uterine myometrial cells into UL. Aim: To study the effect of the TP53 gene variants on the risk of development and clinical features of UL. Materials and Methods: Case-control study was performed using molecular genetic analyses of variants rs1042522 (119 G>C) and rs1625895 (13494G>A) of TP53 gene in patients with UL and comparison group of healthy women. Results: Investigated TP53 gene variants were not associated with the risk of UL development. The patients with the 13494GG genotype (rs1625895) had significantly more often subserous UL (р < 0.05). In patients with heterozygous variant of TP53 — 13494GA genotype (rs1625895) intramural UL was observed (р < 0.05). Conclusions: The rs1625895 (13494G>A) variant of TP53 gene was associated with UL localization. The identified dependence of the UL localization on the TP53 gene variant could be useful for personalized approach to treatment.
References
Tokarz J, Adamski J, Rižner TL. Metabolomics for diagnosis and prognosis of uterine diseases? A systematic review. J Pers Med 2020; 10: 294.
Ciarmela P, Islam MS, Reis FM, et al. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update 2011; 17: 772–90.
Moravek MB, Yin P, Coon JS 5th, et al. Paracrine pathways in uterine leiomyoma stem cells involve insulinlike growth factor 2 and insulin receptor a. J Clin Endocrinol Metab 2017; 102: 1588–95.
Reis FM, Bloise E, Ortiga-Carvalho TM. Hormones and pathogenesis of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2016; 34: 13–24.
De Souza C, Madden J, Koestler DC, et al. Effect of the p53 P72R polymorphism on mutant TP53 allele selection in human cancer. J Natl Cancer Inst 2021: djab019.
De Souza C, Madden JA, Minn D, et al. The P72R polymorphism in R248Q/W p53 mutants modifies the mutant effect on epithelial to mesenchymal transition phenotype and cell invasion via CXCL1 expression. Int J Mol Sci 2020; 21: 8025.
Diakite B, Kassogue Y, Dolo G, et al. p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies. BMC Med Genet 2020; 21: 206.
Liang Y, Zhang X, Chen X, et al. Diagnostic value of progesterone receptor, p16, p53 and pHH3 expression in uterine atypical leiomyoma. Int J Clin Exp Pathol 2015; 8: 7196–202.
IARC TP53 Database. Release R20, 2019. Available from https://www-p53.iarc.fr/.
Lajin B, Alachkar A, Alhaj SA. Duplex detection of TP53 Arg72Pro and 16 bp del/ins polymorphisms by a simple optimized PCR-RFLP method. N Am J Med Sci 2012; 4: 212–5.
Hu Z, Li C, Chen K, et al. Single nucleotide polymorphisms in selected apoptotic genes and BPDE-induced apoptotic capacity in apparently normal primary lymphocytes: a genotype-phenotype correlation analysis. J Cancer Epidemiol 2008; 2008: 147905.
Zhang G, Xu Q, Wang Z, et al. p53 protein expression affected by TP53 polymorphism is associated with the biological behavior and prognosis of low rectal cancer. Oncol Lett 2019; 18: 6807–21.
Proestling K, Hebar A, Pruckner N, et al. The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. PLoS One 2012; 7: e47325.
Shen CC, Cheng WY, Lee CH, et al. Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment. BMC Cancer 2020; 20: 709.
Sharma S, Sambyal V, Guleria K, et al. TP53 polymorphisms in sporadic North Indian breast cancer patients. Asian Pac J Cancer Prev 2014; 15: 6871–9.
Hsieh YY, Chang CC, Tsai FJ, et al. Tumor necrosis factor-alpha-308 promoter and p53 codon 72 gene polymorphisms in women with leiomyomas. Fertil Steril 2004; 82: 1177–81.
Ziaei E, Chaleshtori MH, Ziaei A, et al. Polymorphisms of p53 promoter and susceptibility to uterine leiomyoma. Clin Exp Obstet Gynecol 2016; 43: 713–7.
Patrikis MI, Bryan EJ, Thomas NA, et al. Mutation analysis of CDP, TP53, and KRAS in uterine leiomyomas. Mol Carcinog 2003; 37: 61–4.
Denschlag D, Bettendorf H, Watermann D, et al. Polymorphism of the p53 tumor suppressor gene is associated with susceptibility to uterine leiomyoma. Fertil Steril 2005; 84: 162–6.
Yaghmaei M, Salimi S, Namazi L, et al. Association of XRCC1 Arg399GIn and Tp53 Arg72Pro polymorphisms and increased risk of uterine leiomyoma — A case-control study. Genet Mol Biol 2015; 38: 444–9.
Altinkaya SO, Avcioglu SN, Sezer SD, et al. Analysis of TP53 gene in uterine myomas: No mutations but P72R polymorphism is associated with myoma development. J Obstet Gynaecol Res 2019; 45: 2088–94.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
